Sentences with phrase «allogeneic therapy»

For instance, during emergency care, allogeneic therapy is usually the only relevant option due to the time constraints of autologous cell expansion.

Not exact matches

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

The latest developments in CAR - T translation and manufacturing including alternate gene transfer methods to deliver CARs; novel gene editing approaches, advances in CAR design to improve safety and efficacy, and progress in creating an «off - the - shelf» allogeneic CAR - T therapy.

Although these data show that successful use of allogeneic MSC in regenerative therapy is possible, such approaches are unlikely to be broadly acceptable until it is understood why MSC are not rejected.

Passive immunization, herein referred to as adoptive T cell therapy, is the transfusion of autologous or allogeneic T cells into tumor - bearing hosts, i.e., patients.

Allogeneic stem cell transplantation to leukaemic patients, in which the patient's own diseased bone marrow is replaced by healthy donor material, is one of the best - established and most effective immunological therapies.

Allogeneic cell therapies involving primary cell types such as bone marrow mesenchymal stromal / stem cells (BM - MSCs), hematopoietic stem and progenitor cells (HSPCs), and T and natural killer (NK) cells for immunotherapy applications are especially challenging because of the vigorous process of screening...

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

Furthermore, later - stage DSTs (such as those focusing on regulation) or higher level strategic tools (such as those focusing on portfolio management) might be readily applied to both autologous and allogeneic cell therapies.

Allogeneic Cell Therapy Bioprocess Economics and Optimization: Single - Use Cell Expansion Technologies.

Allogeneic cell therapies from primary cells for immunotherapy applications are especially challenging because of the vigor with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.

Compared with the toxicity that we see with allogeneic donor hematopoietic stem cell therapy, these toxicities are relatively manageable with close monitoring and close supportive care.

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

It offers to the commercialization of unrelated donor - patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.